3 research outputs found
Recommended from our members
The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1- hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting ß2-adrenoceptor agonist
The optimisation of two series of 4-hydroxybenzothiazolone derived ß2-adrenoceptor agonists, bearing a-substituted cyclopentyl and ß-phenethyl amino-substituents, as inhaled long-acting bronchodilators is described. Analogues were selected for synthesis using a lipophilicity based hypothesis to achieve the targeted rapid onset of action in combination with a long duration of action. The profiling of the two series led to identification of the a-substituted cyclopentyl analogue 2 as the optimal compound with a comparable profile to the inhaled once-daily long-acting ß2-adrenoceptor agonist indacaterol. On the basis of these data 2 was promoted as the backup development candidate to indacaterol from the Novartis LABA project. © 2014 Elsevier Ltd. All rights reserved
Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. SARs, Structural Analysis, and Biological Characterization
New
potent, selective monoacylglycerol lipase (MAGL) inhibitors
based on the azetidin-2-one scaffold ((±)-5a–v, (±)-6a–j, and (±)-7a–d) were developed as irreversible ligands,
as demonstrated by enzymatic and crystallographic studies for (±)-5d, (±)-5l, and (±)-5r. X-ray analyses combined with extensive computational studies allowed
us to clarify the binding mode of the compounds. 5v was
identified as selective for MAGL when compared with other serine hydrolases.
Solubility, in vitro metabolic stability, cytotoxicity,
and absence of mutagenicity were determined for selected analogues.
The most promising compounds ((±)-5c, (±)-5d, and (±)-5v) were used for in
vivo studies in mice, showing a decrease in MAGL activity
and increased 2-arachidonoyl-sn-glycerol levels in
forebrain tissue. In particular, 5v is characterized
by a high eudysmic ratio and (3R,4S)-5v is one of the most potent irreversible inhibitors
of h/mMAGL identified thus far.
These results suggest that the new MAGL inhibitors have therapeutic
potential for different central and peripheral pathologies
Development of Potent and Selective Monoacylglycerol Lipase Inhibitors. SARs, Structural Analysis, and Biological Characterization
New
potent, selective monoacylglycerol lipase (MAGL) inhibitors
based on the azetidin-2-one scaffold ((±)-5a–v, (±)-6a–j, and (±)-7a–d) were developed as irreversible ligands,
as demonstrated by enzymatic and crystallographic studies for (±)-5d, (±)-5l, and (±)-5r. X-ray analyses combined with extensive computational studies allowed
us to clarify the binding mode of the compounds. 5v was
identified as selective for MAGL when compared with other serine hydrolases.
Solubility, in vitro metabolic stability, cytotoxicity,
and absence of mutagenicity were determined for selected analogues.
The most promising compounds ((±)-5c, (±)-5d, and (±)-5v) were used for in
vivo studies in mice, showing a decrease in MAGL activity
and increased 2-arachidonoyl-sn-glycerol levels in
forebrain tissue. In particular, 5v is characterized
by a high eudysmic ratio and (3R,4S)-5v is one of the most potent irreversible inhibitors
of h/mMAGL identified thus far.
These results suggest that the new MAGL inhibitors have therapeutic
potential for different central and peripheral pathologies